Abstract
Since cancer vaccines do not always elicit beneficial effects in treated patients, identification of biomarkers for predicting clinical outcomes would be highly desirable. We previously reported that abnormal granulocytes present in peripheral blood mononuclear cells (PBMC) may contribute to poor prognosis in advanced prostate cancer patients receiving personalized peptide vaccination (PPV). In the current study, we examined whether soluble factors derived from granulocytes, such as matrix metalloproteinase 9 (MMP-9), myeloperoxidase (MPO), and arginase 1 (ARG1), and inhibitory cytokine TGFβ in pre-vaccination plasma were useful for predicting prognosis after PPV in advanced cancer patients. In biliary tract cancer (n=25), multivariate Cox regression analysis demonstrated that patients with higher plasma MMP-9 levels had a significantly worse overall survival (OS) [hazard ratio (HR) = 4.637, 95% confidence interval (CI) = 1.670 - 12.877, P = 0.003], whereas MPO, ARG1, or TGFβ levels were not correlated with OS. Similarly, patients with higher MMP-9 levels showed worse prognosis than those with lower MMP-9 levels in other types of advanced cancers, including non-small cell lung cancer (n=32, P = 0.037 by log-rank test), and panc...Continue Reading
References
Oct 2, 2003·International Journal of Cancer. Journal International Du Cancer·Matthew G TuttonA Muti Abulafi
Oct 19, 2004·Cancer Cell·Li YangP Charles Lin
Aug 2, 2005·Nature Reviews. Immunology·Vincenzo Bronte, Paola Zanovello
Sep 21, 2006·Cancer Science·Kyogo Itoh, Akira Yamada
Aug 25, 2007·Cancer Metastasis Reviews·Michelle D Martin, Lynn M Matrisian
Jan 14, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mercedes N LópezFlavio Salazar-Onfray
Feb 11, 2010·Cancer Immunology, Immunotherapy : CII·Masanori NoguchiKyogo Itoh
Apr 24, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Tetsuro SasadaKyogo Itoh
Jun 16, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aram F HezelAndrew X Zhu
Sep 10, 2010·Journal of the National Cancer Institute·Axel HoosJedd Wolchok
Oct 12, 2010·Cancer Biology & Therapy·Masanori NoguchiKyogo Itoh
Dec 2, 2010·Clinical Chemistry and Laboratory Medicine : CCLM·Kalle KisandAgu Tamm
Dec 15, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mizuhiko TerasakiKyogo Itoh
Jan 12, 2011·Cancer Immunology, Immunotherapy : CII·Mary L Disis
Jan 21, 2011·Cancer Metastasis Reviews·Eric TartourS Oudard
May 3, 2011·Blood·Sally M AmosMichael H Kershaw
Nov 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne L TopalianDrew M Pardoll
Nov 11, 2011·Cancer·Nobukazu KomatsuTetsuro Sasada
Dec 24, 2011·Nature·Ira MellmanGlenn Dranoff
Mar 8, 2012·Journal of the National Cancer Institute·Jeffrey Schlom
Sep 13, 2012·Experimental and Therapeutic Medicine·Munehiro YoshitomiHisafumi Kinoshita
Jun 21, 2013·Oncology Reports·Shigeru YutaniTetsuro Sasada
Jan 30, 2014·Cancers·Antonietta Rosella Farina, Andrew Reay Mackay
Feb 15, 2014·Current Medicinal Chemistry·Tetsuro SasadaKyogo Itoh
Feb 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H JohnsonPaul A Bunn
Sep 11, 2014·The New England Journal of Medicine·David P RyanNabeel Bardeesy